Mymetics Corp (MYMX)

[bow-tie]

Meanwhile, in the U.S., a controversy erupted around Sanofi’s work on a Zika vaccine. The French drugmaker was practically forced out of a Zika vaccine development alliance with the U.S. Army. Despite the fact that their government-funded candidate was still in the early stages of development, lawmakers demanded that Sanofi set a price limit for the shot, should it ever hit the market. Sanofi refused, and the episode drew intense public and political scrutiny, and as the controversy raged, HHS’ Biomedical Advanced Research and Development Authority withdrew funding, tanking the program. That vaccine later returned promising results from a trio of phase 1 studies.
RELATED: After a phase 3 flop, Sanofi cans its C. diff vaccine hopes
Then, in December, Sanofi abandoned its late-stage C. difficile program after an interim analysis turned negative, leaving Pfizer and Valneva on track to split a market potentially worth $1 billion.
Elsewhere in R&D, Sanofi is developing a live attenuated RSV vaccine for infants under an NIH deal. Last March, it teamed up with AstraZeneca’s MedImmune to co-develop a monoclonal antibody to prevent RSV. But many companies—such as Novavax, Pfizer and Bavarian Nordic—are all eyeing the same field.

https://www.fiercepharma.com/special-report/3-sanofi